Elanco Animal Health Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the annual meeting of shareholders held by Elanco Animal Health Incorporated on May 21, 2026. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote and approved by shareholders:
- Proposal 1: Election of Directors. All nominees were elected to one-year terms. Notable voting statistics include:
- Kapila K. Anand: 375,459,071 For; 91,840,502 Against.
- Paul Herendeen: 441,252,058 For; 26,575,629 Against.
- Michael Harrington: 373,406,333 For; 94,421,261 Against.
- Lawrence Kurzius: 442,964,897 For; 24,863,542 Against.
- Kirk McDonald: 440,842,458 For; 26,978,663 Against.
- Proposal 2: Ratification of Auditors. Ernst & Young LLP was ratified as the independent registered public accounting firm for 2026 with 480,470,647 votes For and 2,611,450 votes Against.
- Proposal 3: Executive Compensation. The compensation of named executive officers was approved via a non-binding vote with 383,528,222 votes For and 84,173,798 votes Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast against specific directors, particularly Kapila K. Anand and Michael Harrington, who received significant "Against" votes.
- Confirm the term end date for the newly elected directors (2027 annual meeting).
- Review the full proxy statement for details on the specific compensation packages approved in Proposal 3.